Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface.

Koach J, Holien JK, Massudi H, Carter DR, Ciampa OC, Herath M, Lim T, Seneviratne JA, Milazzo G, Murray JE, McCarroll JA, Liu B, Mayoh C, Keenan B, Stevenson BW, Gorman MA, Bell JL, Doughty L, Hüttelmaier S, Oberthuer A, Fischer M, Gifford AJ, Liu T, Zhang X, Zhu S, Gustafson WC, Haber M, Norris MD, Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM.

Cancer Res. 2019 Sep 9. pii: canres.1112.2019. doi: 10.1158/0008-5472.CAN-19-1112. [Epub ahead of print]

PMID:
31501192
2.

Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse.

Zhang L, He X, Liu X, Zhang F, Huang LF, Potter AS, Xu L, Zhou W, Zheng T, Luo Z, Berry KP, Pribnow A, Smith SM, Fuller C, Jones BV, Fouladi M, Drissi R, Yang ZJ, Gustafson WC, Remke M, Pomeroy SL, Girard EJ, Olson JM, Morrissy AS, Vladoiu MC, Zhang J, Tian W, Xin M, Taylor MD, Potter SS, Roussel MF, Weiss WA, Lu QR.

Cancer Cell. 2019 Sep 16;36(3):302-318.e7. doi: 10.1016/j.ccell.2019.07.009. Epub 2019 Aug 29.

PMID:
31474569
3.

Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT.

Seo Y, Huh Y, Huang SY, Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, Matthay KK.

Med Phys. 2019 May;46(5):2477-2486. doi: 10.1002/mp.13446. Epub 2019 Mar 12.

PMID:
30761545
4.

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K.

J Clin Invest. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4.

5.

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA.

Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.

6.

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.

Vo KT, Karski EE, Nasholm NM, Allen S, Hollinger F, Gustafson WC, Long-Boyle JR, Shiboski S, Matthay KK, DuBois SG.

Oncotarget. 2017 Apr 4;8(14):23851-23861. doi: 10.18632/oncotarget.12904.

7.

N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.

Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON.

Cancer Cell. 2016 Apr 11;29(4):536-547. doi: 10.1016/j.ccell.2016.03.001. Epub 2016 Mar 31.

8.

Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Parisi MT, Shulkin BL, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1396. No abstract available.

PMID:
27044383
9.

Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging in vivo.

Yu D, Dong Z, Gustafson WC, Ruiz-González R, Signor L, Marzocca F, Borel F, Klassen MP, Makhijani K, Royant A, Jan YN, Weiss WA, Guo S, Shu X.

Protein Sci. 2016 Feb;25(2):308-15. doi: 10.1002/pro.2843. Epub 2015 Dec 31.

10.

Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):474-481. doi: 10.1007/s00259-015-3179-2. Epub 2015 Sep 4. Erratum in: Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1396.

11.

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.

Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC.

Front Oncol. 2015 May 12;5:111. doi: 10.3389/fonc.2015.00111. eCollection 2015.

12.

A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition.

Meyerowitz JG, Weiss WA, Gustafson WC.

Mol Cell Oncol. 2015 Feb 25;2(2):e975641. doi: 10.4161/23723556.2014.975641. eCollection 2015 Apr-Jun.

13.

The genetics of splicing in neuroblastoma.

Chen J, Hackett CS, Zhang S, Song YK, Bell RJ, Molinaro AM, Quigley DA, Balmain A, Song JS, Costello JF, Gustafson WC, Van Dyke T, Kwok PY, Khan J, Weiss WA.

Cancer Discov. 2015 Apr;5(4):380-95. doi: 10.1158/2159-8290.CD-14-0892. Epub 2015 Jan 30.

14.

Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.

Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, Kozlov S, Mao JH, Van Dyke T, Kwok PY, Khan J, Balmain A, Fan Q, Weiss WA.

Cell Rep. 2014 Nov 6;9(3):1034-46. doi: 10.1016/j.celrep.2014.09.046. Epub 2014 Oct 23.

15.

Drugging MYCN through an allosteric transition in Aurora kinase A.

Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA.

Cancer Cell. 2014 Sep 8;26(3):414-427. doi: 10.1016/j.ccr.2014.07.015. Epub 2014 Aug 28.

16.

An improved monomeric infrared fluorescent protein for neuronal and tumour brain imaging.

Yu D, Gustafson WC, Han C, Lafaye C, Noirclerc-Savoye M, Ge WP, Thayer DA, Huang H, Kornberg TB, Royant A, Jan LY, Jan YN, Weiss WA, Shu X.

Nat Commun. 2014 May 15;5:3626. doi: 10.1038/ncomms4626.

17.

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.

Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF.

Science. 2014 Jan 10;343(6167):189-193. doi: 10.1126/science.1239947. Epub 2013 Dec 12.

18.

EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA.

Cancer Cell. 2013 Oct 14;24(4):438-49. doi: 10.1016/j.ccr.2013.09.004.

19.

Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K.

Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.

20.

Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.

Cheng CK, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12722-7. doi: 10.1073/pnas.1202492109. Epub 2012 Jul 16.

21.

Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.

Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK.

Mol Imaging Biol. 2012 Dec;14(6):735-42. doi: 10.1007/s11307-012-0552-4.

22.

Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.

Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA.

Sci Transl Med. 2012 Jan 4;4(115):115ra3. doi: 10.1126/scitranslmed.3002977.

23.

Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.

Gustafson WC, Matthay KK.

Expert Rev Neurother. 2011 Oct;11(10):1411-23. doi: 10.1586/ern.11.103. Review.

PMID:
21955198
24.

Addiction to B-MYB.

Gustafson WC, Weiss WA.

Oncotarget. 2010 Aug;1(4):235-6. No abstract available.

25.

Myc proteins as therapeutic targets.

Gustafson WC, Weiss WA.

Oncogene. 2010 Mar 4;29(9):1249-59. doi: 10.1038/onc.2009.512. Epub 2010 Jan 25.

26.

Role of gastrointestinal hormones in neuroblastoma.

Gustafson WC, De Berry BB, Evers BM, Chung DH.

World J Surg. 2005 Mar;29(3):281-6. Review.

PMID:
15706438
27.

Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.

Ray S, Lu Y, Kaufmann SH, Gustafson WC, Karp JE, Boldogh I, Fields AP, Brasier AR.

J Biol Chem. 2004 Aug 20;279(34):35604-15. Epub 2004 May 21.

28.

Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.

Gustafson WC, Ray S, Jamieson L, Thompson EA, Brasier AR, Fields AP.

J Biol Chem. 2004 Mar 5;279(10):9400-8. Epub 2003 Dec 10.

29.

Characterization of the role of protein kinase C isozymes in colon carcinogenesis using transgenic mouse models.

Fields AP, Murray NR, Gustafson WC.

Methods Mol Biol. 2003;233:539-53. No abstract available.

PMID:
12840533
30.

Protein kinase C in disease: cancer.

Fields AP, Gustafson WC.

Methods Mol Biol. 2003;233:519-37. No abstract available.

PMID:
12840532
31.

Genomic analysis of glucocorticoid-regulated promoters in murine T-lymphoma cells.

Chen L, Finnerty C, Gustafson WC, Bush CR, Chi P, Guo H, Luxon B, Fields AP, Thompson EA.

Recent Prog Horm Res. 2003;58:155-74. Review.

PMID:
12795418
32.

Comparison of GLUT1, GLUT3, and GLUT4 mRNA and the subcellular distribution of their proteins in normal human muscle.

Stuart CA, Wen G, Gustafson WC, Thompson EA.

Metabolism. 2000 Dec;49(12):1604-9.

PMID:
11145124
33.

Nucleolar protein p120 contains an arginine-rich domain that binds to ribosomal RNA.

Gustafson WC, Taylor CW, Valdez BC, Henning D, Phippard A, Ren Y, Busch H, Durban E.

Biochem J. 1998 Apr 15;331 ( Pt 2):387-93.

34.

Overexpression of human nucleolar proteins in insect cells: characterization of nucleolar protein p120.

Ren Y, Busch R, Durban E, Taylor C, Gustafson WC, Valdez B, Li YP, Smetana K, Busch H.

Protein Expr Purif. 1996 Mar;7(2):212-9.

PMID:
8812864
35.

Functional domains of nucleolar phosphoprotein p120.

Durban E, Valdez BC, Gustafson WC, Taylor CW, Cardellini E, Busch H.

Physiol Chem Phys Med NMR. 1995;27(4):303-11.

PMID:
8768786

Supplemental Content

Loading ...
Support Center